SCHEMBL16674647

SCHEMBL16674647

C[C@@H]1CN(C(=O)OC(C)(C)C)CC[C@H]1NC(=O)OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.50
GPR119 Q8TDV5 2/20 0.49
JAK2 O60674 1/20 0.49
JAK1 P23458 1/20 0.49
STS P08842 1/20 0.49
CTSK P43235 2/20 0.48
HTT P42858 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
CPB1 P15086 1/20 0.47
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
USP30 Q70CQ3 2/20 0.46
PDE4B Q07343 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23233903 1.00 HSD11B1 (0.50) HSD11B1GPR119JAK2JAK1STS
SCHEMBL23226921 1.00 HSD11B1 (0.50) HSD11B1GPR119JAK2JAK1STS
SCHEMBL26627467 0.95 HSD11B1 (0.48) HSD11B1GPR119JAK2JAK1STS
SCHEMBL31520619 0.92 PDE4B (0.54) HSD11B1GPR119JAK2JAK1STS
SCHEMBL29492127 0.92 HSD11B1 (0.50) HSD11B1GPR119JAK2JAK1STS
SCHEMBL5439243 0.91 CTSK (0.58) HSD11B1GPR119JAK2JAK1STS
SCHEMBL2348333 0.91 CTSK (0.58) HSD11B1GPR119JAK2JAK1STS
SCHEMBL2350078 0.91 CTSK (0.58) HSD11B1GPR119JAK2JAK1STS
SCHEMBL2348338 0.91 CTSK (0.58) HSD11B1GPR119JAK2JAK1STS
SCHEMBL10239796 0.90 PDE4B (0.50) STSCTSKL3MBTL1CPB1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174652-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-06-22 US disclosed
US-9434700-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION 2016-09-06 US disclosed
US-20150119405-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174652-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 HSD11B1 3900/4885GPR119 589/4885JAK2 126/4885
US-20150119405-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 HSD11B1 3900/4885GPR119 589/4885JAK2 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.